For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| Collaboration revenue | 0 | |||
| Research and development | 56,103,000 | |||
| General and administrative | 28,666,000 | |||
| Restructuring expenses | 0 | |||
| Total operating expenses | 84,769,000 | |||
| Loss from operations | -84,769,000 | |||
| Other income, net | 9,889,000 | |||
| Net loss | -74,880,000 | |||
| Unrealized gain on marketable securities | 44,000 | |||
| Total other comprehensive gain | 44,000 | |||
| Comprehensive loss | -74,836,000 | |||
| Basic EPS | -1.18 | |||
| Diluted EPS | -1.18 | |||
| Basic Average Shares | 63,355 | |||
| Diluted Average Shares | 63,355 | |||
Fulcrum Therapeutics, Inc. (FULC)
Fulcrum Therapeutics, Inc. (FULC)